



Press release
May 31, 2018
Gothenburg

Increase in the number of shares and votes in Vitrolife AB

Due to stock split 5:1, implemented in accordance with the decision of the Annual General Meeting, the number of shares in Vitrolife AB has increased from 21,710,115 to 108,550,575, with an equal number of votes. The share capital remains unchanged SEK 22,144,317.

May 31, 2018
Gothenburg
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Contact persons:

Thomas Axelsson, CEO, tel: +46 31 721 80 01
Mikael Engblom, CFO, tel: +46 31 721 80 14

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction.

Vitrolife today has approximately 370 employees and the company's products are sold in approximately 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg. Corporate ID number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Website: www.vitrolife.com
This information is information that Vitrolife AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 10.00 am CET on May 31, 2018.